Literature DB >> 23137542

Preferential involvement of Na⁺/Ca²⁺ exchanger type-1 in the brain damage caused by transient focal cerebral ischemia in mice.

Nobutaka Morimoto1, Satomi Kita, Masamitsu Shimazawa, Hiroko Namimatsu, Kazuhiro Tsuruma, Kazuhide Hayakawa, Kenichi Mishima, Nobuaki Egashira, Takuya Iyoda, Ichiro Horie, Yusuke Gotoh, Katsunori Iwasaki, Michihiro Fujiwara, Toshio Matsuda, Akemichi Baba, Issei Komuro, Kyoji Horie, Junji Takeda, Takahiro Iwamoto, Hideaki Hara.   

Abstract

The Na(+)/Ca(2+) exchanger (NCX), an ion-transporter located in the plasma membrane of neuronal cells, contributes to intracellular Ca(2+) homeostasis. Within the brain, three isoforms (NCX1, NCX2, and NCX3) are widely distributed. However, it is not clear to what extent these isoforms are involved in ischemic brain damage in mammals. We therefore used genetically altered mice and isoform-selective NCX inhibitors in a model of transient focal ischemia to investigate the role of each NCX isoform in ischemic brain damage. NCX isoform-mutant mice (NCX1(+/-), NCX2(+/-), and NCX3(+/-)) and wild-type mice were subjected to 90min of middle cerebral artery occlusion (MCAO) followed by 24h of reperfusion. One of three NCX inhibitors [SN-6, KB-R7943, or SEA0400 (3 or 10mgkg(-1), i.p.)] was administered to ddY mice at 30min before more prolonged (4-h) MCAO followed by 24h of reperfusion. After transient MCAO reperfusion, the cerebral infarcts in NCX1(+/-) mice, but not those in NCX2(+/-) or NCX3(+/-) mice, were significantly smaller than those in wild-type mice. SN-6 and SEA0400, which are more selective for the NCX1 isoform, significantly reduced the infarct volume at 10mg/kg. In contrast, KB-R7943, which is more selective for NCX3, did not. These results suggest that the NCX1 isoform may act preferentially (vs. the NCX2 and NCX3 isoforms) to exacerbate the cerebral damage caused by ischemic insult in mice, and that NCX1-selective inhibitors warrant investigation as a potential therapeutic agents for stroke.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23137542     DOI: 10.1016/j.bbrc.2012.10.114

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  MicroRNA-103-1 selectively downregulates brain NCX1 and its inhibition by anti-miRNA ameliorates stroke damage and neurological deficits.

Authors:  Antonio Vinciguerra; Luigi Formisano; Pierpaolo Cerullo; Natascia Guida; Ornella Cuomo; Alba Esposito; Gianfranco Di Renzo; Lucio Annunziato; Giuseppe Pignataro
Journal:  Mol Ther       Date:  2014-06-23       Impact factor: 11.454

Review 2.  The role of Na+/Ca2+ exchanger subtypes in neuronal ischemic injury.

Authors:  Botros Shenoda
Journal:  Transl Stroke Res       Date:  2015-04-11       Impact factor: 6.829

3.  Involvement of the sodium-calcium exchanger 3 (NCX3) in ziram-induced calcium dysregulation and toxicity.

Authors:  J Jin; A J Lao; M Katsura; A Caputo; F E Schweizer; S Sokolow
Journal:  Neurotoxicology       Date:  2014-10-02       Impact factor: 4.294

4.  Na+/Ca2+ exchanger mediates cold Ca2+ signaling conserved for temperature-compensated circadian rhythms.

Authors:  Naohiro Kon; Hsin-Tzu Wang; Yoshiaki S Kato; Kyouhei Uemoto; Naohiro Kawamoto; Koji Kawasaki; Ryosuke Enoki; Gen Kurosawa; Tatsuto Nakane; Yasunori Sugiyama; Hideaki Tagashira; Motomu Endo; Hideo Iwasaki; Takahiro Iwamoto; Kazuhiko Kume; Yoshitaka Fukada
Journal:  Sci Adv       Date:  2021-04-30       Impact factor: 14.136

Review 5.  Relevant mediators involved in and therapies targeting the inflammatory response induced by activation of the NLRP3 inflammasome in ischemic stroke.

Authors:  Qingxue Xu; Bo Zhao; Yingze Ye; Yina Li; Yonggang Zhang; Xiaoxing Xiong; Lijuan Gu
Journal:  J Neuroinflammation       Date:  2021-05-31       Impact factor: 8.322

Review 6.  Roles of Na+/Ca2+ exchanger 1 in digestive system physiology and pathophysiology.

Authors:  Qiu-Shi Liao; Qian Du; Jun Lou; Jing-Yu Xu; Rui Xie
Journal:  World J Gastroenterol       Date:  2019-01-21       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.